AKT1 E17K mutant phosphorylates TSC2, inhibiting it

Stable Identifier
R-HSA-2399982
Type
Reaction
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Summation

AKT1 E17K gain-of-function mutant is expected to phosphorylate TSC2 and inhibit it, like the wild-type AKT (Inoki et al. 2002, Manning et al. 2002), but this has not been experimentally tested.

Literature References
PubMed ID Title Journal Year
12150915 Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, BD, Tee, AR, Logsdon, MN, Blenis, J, Cantley, LC

Mol Cell 2002
12172553 TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K, Li, Y, Zhu, T, Wu, J, Guan, KL

Nat Cell Biol 2002
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein serine/threonine kinase activity of p-T308,S473-AKT1 E17K [cytosol]
Physical Entity
Activity
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed